Back to resultsA Study to Determine the Effect of WelChol Tablets on Cholesterol in Patients Who Have Been Taking Pravastatin for at Least 4 Weeks.
Primary Purpose
Hypercholesterolemia
Status
Completed
Phase
Phase 4
Locations
United States
Study Type
Interventional
Intervention
pravastatin tablets and Welchol tablets
pravastatin tablets and Welchol placebo tablets
Sponsored by
About this trial
This is an interventional treatment trial for Hypercholesterolemia
Eligibility Criteria
Inclusion Criteria:
- Male or female > or = to 18 years of age
- On a stable dose of pravastatin
- LDL-C > or = to 100 mg/dL and < or = 250 mg/dL
- Triglycerides < or = to 300 mg/dL
- Women are not pregnant or breast-feeding or planning to become pregnant
- Women have had a hysterectomy or tubal ligation, or who are post-menopausal or who practice an accepted method of birth control as specified in the protocol
Exclusion Criteria:
- BMI > 40 kg/m2
- History of allergic or toxic reaction to colesevelam HCL
- History of swallowing disorder
- Any serious condition that would interfere with the conduct of the study
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Placebo Comparator
Arm Label
1
2
Arm Description
pravastatin tablets and Welchol tablets
pravastatin tablets and Welchol placebo tablets
Outcomes
Primary Outcome Measures
The primary efficacy parameter was the percent change in LDL-C from baseline to endpoint.
Secondary Outcome Measures
The absolute change in LDL-C from baseline to endpoint.
The absolute change and % change of total cholesterol from baseline to endpoint
The absolute change and % change of triglycerides from baseline to endpoint
The absolute change and % change of HDL-C from baseline to endpoint
The absolute change and % change of c-reactive protein from baseline to endpoint
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT00755352
Brief Title
A Study to Determine the Effect of WelChol Tablets on Cholesterol in Patients Who Have Been Taking Pravastatin for at Least 4 Weeks.
Official Title
Efficacy of WelChol as an Add-on to Pravastatin Therapy
Study Type
Interventional
2. Study Status
Record Verification Date
April 2015
Overall Recruitment Status
Completed
Study Start Date
November 2002 (undefined)
Primary Completion Date
June 2003 (Actual)
Study Completion Date
April 2005 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Daiichi Sankyo, Inc.
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
Determine the effect of WelChol tablets on serum lipids, lipoproteins, apolipoproteins, and lipoprotein particle size in patients who were stabilized on pravastatin therapy for at least 4 weeks.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypercholesterolemia
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
67 (Actual)
8. Arms, Groups, and Interventions
Arm Title
1
Arm Type
Experimental
Arm Description
pravastatin tablets and Welchol tablets
Arm Title
2
Arm Type
Placebo Comparator
Arm Description
pravastatin tablets and Welchol placebo tablets
Intervention Type
Drug
Intervention Name(s)
pravastatin tablets and Welchol tablets
Intervention Description
pravastatin tablets, 1 tablet/day for 6 weeks; Welchol Tablets, 6 tablets/day for 6 weeks
Intervention Type
Drug
Intervention Name(s)
pravastatin tablets and Welchol placebo tablets
Intervention Description
pravastatin tablets, 1 tablet/day; Welchol placebo tablets, 6 tablets/day
Primary Outcome Measure Information:
Title
The primary efficacy parameter was the percent change in LDL-C from baseline to endpoint.
Time Frame
6 weeks
Secondary Outcome Measure Information:
Title
The absolute change in LDL-C from baseline to endpoint.
Time Frame
6 weeks
Title
The absolute change and % change of total cholesterol from baseline to endpoint
Time Frame
6 Weeks
Title
The absolute change and % change of triglycerides from baseline to endpoint
Time Frame
6 Weeks
Title
The absolute change and % change of HDL-C from baseline to endpoint
Time Frame
6 Weeks
Title
The absolute change and % change of c-reactive protein from baseline to endpoint
Time Frame
6 weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Male or female > or = to 18 years of age
On a stable dose of pravastatin
LDL-C > or = to 100 mg/dL and < or = 250 mg/dL
Triglycerides < or = to 300 mg/dL
Women are not pregnant or breast-feeding or planning to become pregnant
Women have had a hysterectomy or tubal ligation, or who are post-menopausal or who practice an accepted method of birth control as specified in the protocol
Exclusion Criteria:
BMI > 40 kg/m2
History of allergic or toxic reaction to colesevelam HCL
History of swallowing disorder
Any serious condition that would interfere with the conduct of the study
Facility Information:
City
Los Angeles
State/Province
California
Country
United States
City
Castle Rock
State/Province
Colorado
Country
United States
City
Jacksonville
State/Province
Florida
Country
United States
City
Pembroke Pines
State/Province
Florida
Country
United States
City
St. Petersburg
State/Province
Florida
Country
United States
City
Chicago
State/Province
Illinois
Country
United States
City
Indianapolis
State/Province
Indiana
Country
United States
City
Louisville
State/Province
Kentucky
Country
United States
City
Rochester
State/Province
New York
Country
United States
City
Cincinnati
State/Province
Ohio
Country
United States
City
Cleveland
State/Province
Ohio
Country
United States
City
Bartlett
State/Province
Tennessee
Country
United States
City
Norfolk
State/Province
Virginia
Country
United States
City
Richmond
State/Province
Virginia
Country
United States
City
Seattle
State/Province
Washington
Country
United States
12. IPD Sharing Statement
Learn more about this trial
A Study to Determine the Effect of WelChol Tablets on Cholesterol in Patients Who Have Been Taking Pravastatin for at Least 4 Weeks.
We'll reach out to this number within 24 hrs